AI Engines For more Details: Perplexity Kagi Labs You
Anti-inflammatory Effects: Isoflupredone acetate belongs to the class of corticosteroids, which have potent anti-inflammatory properties. It works by suppressing the immune response and reducing inflammation, which helps alleviate symptoms associated with allergic reactions, dermatitis, arthritis, and other inflammatory conditions in animals.
Immunosuppressive Effects: Corticosteroids like isoflupredone acetate can suppress the immune system's activity, which is beneficial in treating autoimmune diseases or conditions where the immune system is overactive and causing harm to the body's tissues. By dampening immune responses, corticosteroids can help manage conditions such as autoimmune hemolytic anemia or immune-mediated skin diseases in animals.
Allergy Relief: Isoflupredone acetate can be effective in managing allergic reactions in animals, including allergic dermatitis (skin inflammation) caused by flea bites, environmental allergens, or food allergies. It reduces itching, inflammation, redness, and swelling associated with allergic skin reactions, providing relief to affected animals.
Respiratory Conditions: Corticosteroids like isoflupredone acetate may be used to manage respiratory conditions in animals, such as asthma, bronchitis, or allergic rhinitis. By reducing airway inflammation and constriction, corticosteroids help improve breathing and alleviate symptoms such as coughing, wheezing, and nasal congestion.
Dermatological Conditions: Isoflupredone acetate can be beneficial in treating various dermatological conditions in animals, including eczema, dermatitis, hot spots (acute moist dermatitis), and allergic reactions. It helps reduce inflammation, itching, and irritation associated with these skin conditions, promoting healing and comfort.
Musculoskeletal Conditions: Corticosteroids like isoflupredone acetate may also be used to manage musculoskeletal conditions in animals, such as arthritis, tendonitis, or bursitis. By reducing inflammation and pain in affected joints or tissues, corticosteroids help improve mobility and quality of life for animals suffering from these conditions.
Ophthalmic Conditions: Isoflupredone acetate may be administered topically or intraocularly to manage certain ophthalmic conditions in animals, such as uveitis (inflammation of the uvea) or allergic conjunctivitis. It helps reduce inflammation and swelling in the eye, relieving pain and discomfort associated with these conditions.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Bacteroides uniformis | Reduces |
| species | Escherichia coli | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| ADHD | 0.2 | 0.2 | |
| Allergic Rhinitis (Hay Fever) | 0.5 | 0.5 | |
| Allergies | 0.7 | 0.7 | |
| Allergy to milk products | 0.6 | 0.3 | 1 |
| Alzheimer's disease | 0.6 | 0.3 | 1 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.5 | 0.5 | 0 |
| Ankylosing spondylitis | 0.8 | 0.3 | 1.67 |
| Anorexia Nervosa | 0.1 | -0.1 | |
| Antiphospholipid syndrome (APS) | 0.5 | 0.5 | |
| Asthma | 0.1 | -0.1 | |
| Atrial fibrillation | 0.1 | 0.4 | -3 |
| Autism | 0.5 | 0.6 | -0.2 |
| benign prostatic hyperplasia | 0.3 | 0.3 | |
| Biofilm | 0.7 | 0.7 | |
| Bipolar Disorder | 0.4 | 0.4 | |
| Brain Trauma | 0.1 | -0.1 | |
| Cancer (General) | 0.1 | -0.1 | |
| Carcinoma | 0.4 | 0.1 | 3 |
| Celiac Disease | 0.6 | 0.1 | 5 |
| Cerebral Palsy | 0.1 | -0.1 | |
| Chronic Fatigue Syndrome | 1.1 | 0.1 | 10 |
| Chronic Kidney Disease | 0.5 | 0.5 | |
| Chronic Lyme | 0.1 | -0.1 | |
| Chronic Urticaria (Hives) | 0.8 | 0.2 | 3 |
| Coagulation / Micro clot triggering bacteria | 0.8 | 0.8 | |
| Colorectal Cancer | 1.1 | 1.1 | |
| Constipation | 0.4 | 0.4 | |
| Coronary artery disease | 0.2 | 0.2 | |
| COVID-19 | 1.2 | 0.4 | 2 |
| Crohn's Disease | 1.5 | 0.3 | 4 |
| cystic fibrosis | 0.8 | 0.1 | 7 |
| deep vein thrombosis | 0.8 | 0.8 | |
| Depression | 0.9 | 0.5 | 0.8 |
| Eczema | 0.4 | 0.2 | 1 |
| Endometriosis | 0.9 | 0.9 | |
| Epilepsy | 0.6 | 0.1 | 5 |
| Fibromyalgia | 0.4 | -0.4 | |
| Functional constipation / chronic idiopathic constipation | 1.1 | 0.3 | 2.67 |
| gallstone disease (gsd) | 0.3 | 0.3 | |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.2 | 0.2 | |
| Generalized anxiety disorder | 1 | 0.1 | 9 |
| Graves' disease | 0.1 | 0.1 | |
| Halitosis | 0.1 | 0.1 | |
| Hashimoto's thyroiditis | 0.1 | 0.1 | 0 |
| High Histamine/low DAO | 0.5 | 0.5 | |
| hyperglycemia | 0.3 | 0.1 | 2 |
| hypertension (High Blood Pressure | 0.4 | 0.3 | 0.33 |
| Hypoxia | 0.1 | 0.1 | |
| IgA nephropathy (IgAN) | 0.4 | -0.4 | |
| Inflammatory Bowel Disease | 1.3 | 0.3 | 3.33 |
| Insomnia | 0.1 | 0.1 | 0 |
| Intelligence | 0.2 | 0.2 | |
| Intracranial aneurysms | 0.1 | 0.1 | |
| Irritable Bowel Syndrome | 0.9 | 0.4 | 1.25 |
| Liver Cirrhosis | 0.4 | 0.1 | 3 |
| Long COVID | 0.5 | 0.1 | 4 |
| Lung Cancer | 0.3 | 0.3 | |
| Mast Cell Issues / mastitis | 0.3 | 0.3 | |
| ME/CFS with IBS | 0.1 | -0.1 | |
| ME/CFS without IBS | 0.2 | 0.1 | 1 |
| Metabolic Syndrome | 1.3 | 0.6 | 1.17 |
| Mood Disorders | 0.9 | 0.5 | 0.8 |
| Multiple Sclerosis | 0.3 | -0.3 | |
| neuropathic pain | 0.1 | -0.1 | |
| Neuropathy (all types) | 0.3 | -0.3 | |
| neuropsychiatric disorders (PANDAS, PANS) | 0.5 | 0.5 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.3 | 0.1 | 2 |
| NonCeliac Gluten Sensitivity | 0.1 | -0.1 | |
| Obesity | 0.5 | 0.2 | 1.5 |
| obsessive-compulsive disorder | 1.4 | 0.3 | 3.67 |
| Osteoarthritis | 0.5 | 0.5 | |
| Osteoporosis | 0.4 | 0.1 | 3 |
| Parkinson's Disease | 1.1 | 0.5 | 1.2 |
| Polycystic ovary syndrome | 0.4 | 0.4 | |
| primary biliary cholangitis | 0.2 | -0.2 | |
| Psoriasis | 0.7 | 0.1 | 6 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 0.5 | 0.3 | 0.67 |
| Schizophrenia | 0.4 | 0.4 | |
| Sjögren syndrome | 0.3 | 0.4 | -0.33 |
| Sleep Apnea | 0.1 | -0.1 | |
| Slow gastric motility / Gastroparesis | 0.6 | 0.6 | |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.5 | 0.5 | |
| Stress / posttraumatic stress disorder | 0.6 | 0.1 | 5 |
| Systemic Lupus Erythematosus | 0.7 | 0.7 | |
| Tourette syndrome | 0.1 | -0.1 | |
| Type 1 Diabetes | 0.6 | 0.6 | |
| Type 2 Diabetes | 1.3 | 1.1 | 0.18 |
| Ulcerative colitis | 1 | 0.4 | 1.5 |
| Unhealthy Ageing | 0.5 | 0.5 | |
| Vitiligo | 0.2 | 0.2 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2024 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription
All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models.
Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [35.170.81 ]
Due to AI drones slamming this site, we have added IP blocking on excessive calls. Email us if you get blocked and send this [35.170.81 ]
